Vitaspring Biomedical Co. Ltd
vitaspring8888.comWhat Do They Do?
Aims to develop cell-based medical technologies using X.msc stem cells and exosome materials for regenerative medicine, preventive health, and wellness, with institutional and clinical clients in mind.
10-K for FY2026, filed Jun 17, 2026
Who Are Their Customers?
Plans to serve institutional and clinical clients, including laboratories, hospitals, and research organizations, through direct sales or distribution partners.
10-K for FY2026, filed Jun 17, 2026Contract Manufacturing and Research Services – We intend to pursue a production platform to offer cell-culture, purification, and testing…View ↗
Product Commercialization and Licensing – Over the longer term, we intend to develop and license cell-based products, exosome formulations…View ↗
We anticipate a business-to-business (B2B) model, serving institutional and clinical clients rather than direct retail customers. Pricing…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2027, filed Sep 17, 2026
−$155.8KView ↗
- ▲ +41% (Loss)
- vs −$110.8K in Q2 FY2026
-
Sep 7, 2026
CEO, CFO and chair leave; successors are appointed
Jing-Zhou Chen became CEO and CFO, and Shao-Hsiang Shih became chair after Ssu-Chuan Lai resigned from those roles.
Sources
8-K, filed Sep 10, 2026
Effective at 11:58 p.m. Pacific Time on September 7, 2026, immediately following the election of her successor as a director and the…View ↗
Loading...
